EASITx study enrollment is now closed.
Thank you for your interest.
Do you think you might have Irritable Bowel Syndrome (IBS)?
More than 30 million Americans are affected by IBS, including symptoms such as:
EASITx uses a digital behavioral therapy approach instead of pills to help participants experience symptom relief.
If you have IBS symptoms, see if you qualify!
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
You may be eligible to participate if you...
What is the purpose of this study?
The goal of this study is to test the effectiveness of a new, smartphone-based digital IBS treatment program. With your help, we will be able to find more convenient, effective, and efficient way to treat symptoms experienced due to IBS.
What should I expect?
If you decide to join this study, you will have one visit with a physician, be asked to complete forms and surveys, access an application on your smartphone, and provide feedback, answering three multiple choice questions, on a daily basis for 28 weeks.

There are follow up surveys at 6-months and 1-year.

Your privacy will be kept secure and private. Only a “participant study number” will be used to when presenting your data to anyone outside of the EASITx Study Team.

You may decide to discontinue your participation at any point in time.
What are the possible benefits of participating?
You may be given the opportunity to receive state-of-the-art investigational treatment for IBS. You will also have the opportunity to provide valuable information to help advance medical care around the world.
Will I be compensated for participating?
You will be compensated up to $525 for the satisfactory completion of this study and its requirements.
What happens to the data provided?
Data will be pseudonymized and shared with the research sponsor to enable the development
of their digital IBS treatment program. The Sponsor hopes to use the data from this clinical trial
to eventually gain FDA approval for their IBS treatment program.
Who is organizing and funding the research?
The Sponsor, metaMe Health, Inc. (222 Merchandise Mart Plaza, Suite 1230, Chicago, IL 60654), is committed to developing FDA-approved prescription digital therapeutics for the treatment of gastrointestinal conditions. They are hoping to deliver effective, safe, and affordable treatment options that patients can easily access through their smartphones.
For any additional questions: